Clinical trials: Embryonal Neoplasm
Cushing's Disease, Acromegaly
Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies
The purpose of this study is to allow continued use of pasireotide in patients who are on pasireotide treatment in a Novartis-sponsored study and are benefiting from the treatment as judged by the investigator.
- Conditions
- Cushing's Disease, Acromegaly, Neuroendocrine Tumors, Pituitary Tumors
- Trial name
- NCT01794793
- Testing
- Pasireotide, Cabergoline, Pasireotide LAR
- Where
- 94 sites in United States, Argentina and 26 more
- Volunteers
- 337 people
- Sponsor
- RECORDATI GROUP
Advanced Solid Tumor, Uveal Melanoma, Metastatic
Safety and Preliminary Efficacy of MBS8(1V270) in Cancer Patients With Advanced Solid Tumours
The Phase I trial is evaluating safety, tolerability, pharmacokinetics and preliminary efficacy of MBS8(1V270) in subjects with advanced solid tumours.
- Conditions
- Advanced Solid Tumor, Uveal Melanoma, Metastatic, Cutaneous Melanoma
- Trial name
- NCT04855435
- Testing
- MBS8(1V270), MBS8(1V270) and pembrolizumab combination
- Where
- 5 sites in Denmark, Spain
- Volunteers
- 106 people
- Sponsor
- MonTa Biosciences ApS
Childhood High-grade Cerebral Astrocytoma, Childhood Oligodendroglioma
Tipifarnib in Treating Young Patients With Recurrent or Progressive High-Grade Glioma, Medulloblastoma, Primitive Neuroectodermal Tumor, or Brain Stem Glioma
This phase II trial is studying how well tipifarnib works in treating young patients with recurrent or progressive high-grade glioma, medulloblastoma, primitive neuroectodermal tumor, or brain stem glioma.
- Conditions
- Childhood High-grade Cerebral Astrocytoma, Childhood Oligodendroglioma, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Cerebellar Astrocytoma
- Trial name
- NCT00070525
- Testing
- tipifarnib
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- National Cancer Institute (NCI)
Renal Cell Carcinoma, Neuroendocrine Tumours
[18]F-FAZA PET Imaging Study in Patients With Cancer of the Head & Neck, Lung, Renal Cell, Brain, Lymphoma and Neuroendocrine Tumours
Positron Emission Tomography (PET) is a Nuclear Medicine procedure that uses positron emitting radiolabeled tracer molecules to visualize biological activity.
- Trial name
- NCT00323076
- Testing
- 18F-FAZA PET Imaging
- Where
- Canada
- Volunteers
- 92 people
- Sponsor
- AHS Cancer Control Alberta
Advanced Nonhaematologic Malignancies
Safety, Efficacy, and Tolerability of BOS172738 in Patients With Advanced Rearranged During Transfection (RET) Gene-Altered Tumors
This study will be conducted to assess the safety and tolerability of BOS172738 when administered to patients with advanced solid tumors with rearranged during transfection (RET) gene alterations and also to establish the maximum…
- Trial name
- NCT03780517
- Testing
- BOS172738
- Where
- 21 sites in United States, Belgium and 5 more
- Volunteers
- 117 people
- Sponsor
- Boston Pharmaceuticals
Neutropenia, Sarcoma
Combination Chemotherapy in Treating Patients With Newly Diagnosed Metastatic Ewing's Sarcoma or Primitive Neuroectodermal Tumor
Phase II trial to study the effectiveness of combination chemotherapy in treating patients with newly diagnosed metastatic Ewing's sarcoma or primitive neuroectodermal tumor.
- Trial name
- NCT00002643
- Testing
- filgrastim, amifostine trihydrate, cyclophosphamide
- Where
- 49 sites in United States, Australia and 3 more
- Volunteers
- 130 people
- Sponsor
- National Cancer Institute (NCI)
Adult Glioblastoma, Adult Gliosarcoma
Temozolomide and Radiation Therapy With or Without Cediranib Maleate in Treating Patients With Newly Diagnosed Glioblastoma
This randomized phase II trial studies temozolomide, radiation therapy, and cediranib maleate to see how well they work compared with temozolomide, radiation therapy, and a placebo in treating patients with newly diagnosed…
- Trial name
- NCT01062425
- Testing
- 3-Dimensional Conformal Radiation Therapy, Cediranib Maleate, Intensity-Modulated Radiation Therapy
- Where
- 105 sites in United States
- Volunteers
- 261 people
- Sponsor
- National Cancer Institute (NCI)
Melanoma BRAF V600E/K Mutated
Surgical or Radiotherapeutic Intervention Concerning Large Singular Stable to Progressive Metastases in Patients With BRAFV600-mutated Melanoma Receiving Treatment With Encorafenib + Binimetinib
This is an open-label, prospective, single arm study conducted in Germany to investigate local treatment (i.e. surgery or radiotherapy or electrochemotherapy) of metastases showing no response to encorafenib (E) + binimetinib (B)…
- Trial name
- SuRage-EB (NCT07092410)
- Testing
- Encorafenib & Binimetinib Treatment
- Sponsor
- SRH Wald-Klinikum Gera GmbH
Retinoblastoma
Combination Chemotherapy and Cyclosporine Followed by Focal Therapy for Bilateral Retinoblastoma
RATIONALE: Drugs used in chemotherapy, such as carboplatin, etoposide, and vincristine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00110110
- Testing
- filgrastim, Carboplatin, Cyclosporine
- Where
- 6 sites in Canada, Chile and 2 more
- Volunteers
- 71 people
- Sponsor
- The Hospital for Sick Children
Gastro-enteropancreatic Neuroendocrine Tumor
A Study of Peptide Receptor Radionuclide Therapy (PRRT) Use in Neuroendocrine Tumor (NET) Patients in Germany
The aim of this study was to assess patient characteristics and treatment patterns of gastro-enteropancreatic neuroendocrine tumor (GEP-NET) patients who received PRRT in German routine care.
- Trial name
- LUNET-2 (NCT07653126)
- Where
- 7 sites in Germany
- Volunteers
- 117 people
- Sponsor
- Novartis Pharmaceuticals
Melanoma
Study of XL888 With Vemurafenib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma
This is a multi-cohort, dose-escalation study of XL888 with a fixed dose of vemurafenib. New dose escalation or de-escalation cohorts will be assigned by the Principal Investigator (PI) with discussion with appropriate…
- Trial name
- NCT01657591
- Testing
- XL888, Vemurafenib
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Adult Giant Cell Glioblastoma, Adult Glioblastoma
Tipifarnib and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase II trial to study the effectiveness of combining tipifarnib with radiation therapy in treating patients who have newly diagnosed glioblastoma multiforme.
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma
- Trial name
- NCT00058097
- Testing
- tipifarnib, radiation therapy
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- National Cancer Institute (NCI)
Melanoma, Gastrointestinal Cancer
Ability of a Dendritic Cell Vaccine to Immunize Melanoma or Epithelial Cancer Patients Against Defined Mutated Neoantigens Expressed by the Autologous Cancer
Background: Exomes are the parts of deoxyribonucleic acid (DNA) that make proteins. Researchers are finding a way to read the letters in the exome. Incorrect letters are called mutations. Tumors contain specific mutations.
- Conditions
- Melanoma, Gastrointestinal Cancer, Breast Cancer, Ovarian Cancer
- Trial name
- NCT03300843
- Testing
- Peptide loaded dendritic cell vaccine
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Solid Tumors, Recurrent or Refractory Medulloblastoma
A Dose Finding and Safety Study of Oral LEQ506 in Patients With Advanced Solid Tumors
This first-in-human dose-escalation study is to characterize the safety, tolerability, pharmacokinetics and pharmacodynamics of LEQ506 given orally on a daily dosing schedule in patients with advanced solid tumors.
- Conditions
- Advanced Solid Tumors, Recurrent or Refractory Medulloblastoma, Locally Advanced or Metastatic Basal Cell Carcinoma
- Trial name
- NCT01106508
- Testing
- LEQ506
- Where
- 5 sites in United States, Netherlands and 2 more
- Volunteers
- 57 people
- Sponsor
- Novartis Pharmaceuticals
Glioblastoma Multiforme, Glycolytic Index
Biologic Association Between Metabolic Magnetic Resonance-positron Emission Tomograph (MR-PET) and Tissue Measures of Glycolysis in Brain Tumors of Infiltrating Glioblastoma Cells
The purpose of this project is to validate a new combined MRI and PET imaging technique as a biomarker or measure of glycolysis in brain tumors.
- Conditions
- Glioblastoma Multiforme, Glycolytic Index, Epidermal Growth Factor Receptor
- Trial name
- NCT06059690
- Testing
- pH Measurement of in vivo tissue
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Melanoma (Skin)
Temozolomide and Sorafenib in Treating Patients With Metastatic or Unresectable Melanoma
RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00602576
- Testing
- sorafenib tosylate, temozolomide
- Where
- United States
- Volunteers
- 169 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Central Nervous System Nongerminomatous Germ Cell Tumor, Choriocarcinoma
A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT
This phase II trial studies the best approach to combine chemotherapy and radiation therapy (RT) based on the patient's response to induction chemotherapy in patients with non-germinomatous germ cell tumors (NGGCT) that have not…
- Conditions
- Central Nervous System Nongerminomatous Germ Cell Tumor, Choriocarcinoma, Embryonal Carcinoma, Immature Teratoma
- Trial name
- NCT04684368
- Testing
- Biospecimen Collection, Carboplatin, Etoposide
- Where
- 170 sites in United States, Australia and 2 more
- Volunteers
- 160 people
- Sponsor
- Children's Oncology Group
Melanoma, Survivors
Health Behaviors, Surveillance, Psychosocial Factors, and Family Concerns
The purpose of this study is to examine the health behaviors of melanoma survivors. We want to know about their thoughts and concerns. Melanoma is a type of skin cancer.
- Conditions
- Melanoma, Survivors, Psychological Factors
- Trial name
- NCT00518050
- Testing
- Focus group, Survey
- Where
- United States
- Volunteers
- 160 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Melanoma
A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma
The purpose of this study is to learn about the effects of three study medicines (encorafenib, binimetinib, and pembrolizumab) given together for the treatment of melanoma that: is advanced or metastatic (spread to other parts of…
- Trial name
- NCT04657991
- Testing
- Encorafenib, Binimetinib, Pembrolizumab
- Where
- 151 sites in United States, Argentina and 25 more
- Volunteers
- 257 people
- Sponsor
- Pfizer
Malignant Melanoma
Phase II Trial of Ontak With Metastatic Melanoma
The purpose of this study is to determine whether ONTAK is an effective treatment in patients with Stage IV Melanoma
- Trial name
- NCT00299689
- Testing
- Denileukin diftitox
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- James Graham Brown Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.